Residual cardiovascular risk among people with diabetes
Type 2 diabetes (T2D) is a growing health concern across both developed and developing countries. Cardiovascular disease (CVD) remains the major cause of increased mortality in this patient population. In recent years, effective low density lipoprotein lowering treatments and other risk reduction st...
Gespeichert in:
| Veröffentlicht in: | Diabetes, obesity & metabolism obesity & metabolism, 2019-04, Vol.21 (S1), p.28-38 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 38 |
|---|---|
| container_issue | S1 |
| container_start_page | 28 |
| container_title | Diabetes, obesity & metabolism |
| container_volume | 21 |
| creator | Dash, Satya Leiter, Lawrence A. |
| description | Type 2 diabetes (T2D) is a growing health concern across both developed and developing countries. Cardiovascular disease (CVD) remains the major cause of increased mortality in this patient population. In recent years, effective low density lipoprotein lowering treatments and other risk reduction strategies have substantially reduced the risk of atherosclerotic CVD, yet patients with T2D continue to remain at increased risk for atherosclerotic CVD. Here, we will briefly review various proposed underlying mechanisms for this residual risk with a more in‐depth focus on the potential role of triglyceride‐rich lipoproteins in residual risk and potential avenues to target this pharmacologically. |
| doi_str_mv | 10.1111/dom.13646 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2211952995</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2211952995</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3536-cf961cd85dee02385e8821038ba8444a9e87ad882d068694ecbc781992f4db83</originalsourceid><addsrcrecordid>eNp10F1LwzAUBuAgipvTC_-AFLzRi275appcyvyEyUB2X9LkVDvbtSarY__euE4vBHNzwuHh5fAidE7wmIQ3sU09JkxwcYCGhAsWE0bF4e5PY6kwHaAT75cYY85keowGjGBMeSKHKH0BX9pOV5HRzpbNp_amq7SLXOnfI103q9eohaatINqU67fIljqHNfhTdFToysPZfo7Q4v5uMX2MZ_OHp-nNLDYsYSI2hRLEWJlYAEyZTEBKSjCTuZacc61AptqGncVCCsXB5CaVRClacJtLNkJXfWzrmo8O_DqrS2-gqvQKms5nlBKiEqpUEujlH7psOrcKx-0UIzSwoK57ZVzjvYMia11Za7fNCM6-y8xCmdmuzGAv9oldXoP9lT_tBTDpwaasYPt_UnY7f-4jvwA0VHwT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2211312299</pqid></control><display><type>article</type><title>Residual cardiovascular risk among people with diabetes</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Dash, Satya ; Leiter, Lawrence A.</creator><creatorcontrib>Dash, Satya ; Leiter, Lawrence A.</creatorcontrib><description>Type 2 diabetes (T2D) is a growing health concern across both developed and developing countries. Cardiovascular disease (CVD) remains the major cause of increased mortality in this patient population. In recent years, effective low density lipoprotein lowering treatments and other risk reduction strategies have substantially reduced the risk of atherosclerotic CVD, yet patients with T2D continue to remain at increased risk for atherosclerotic CVD. Here, we will briefly review various proposed underlying mechanisms for this residual risk with a more in‐depth focus on the potential role of triglyceride‐rich lipoproteins in residual risk and potential avenues to target this pharmacologically.</description><identifier>ISSN: 1462-8902</identifier><identifier>EISSN: 1463-1326</identifier><identifier>DOI: 10.1111/dom.13646</identifier><identifier>PMID: 31002458</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Arteriosclerosis ; cardiovascular disease ; Cardiovascular diseases ; clinical trial ; Developing countries ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; dyslipidaemia ; LDCs ; lipid‐lowering therapy ; Lipoproteins ; Low density lipoprotein ; Metabolic disorders</subject><ispartof>Diabetes, obesity & metabolism, 2019-04, Vol.21 (S1), p.28-38</ispartof><rights>2019 John Wiley & Sons Ltd</rights><rights>2019 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3536-cf961cd85dee02385e8821038ba8444a9e87ad882d068694ecbc781992f4db83</citedby><cites>FETCH-LOGICAL-c3536-cf961cd85dee02385e8821038ba8444a9e87ad882d068694ecbc781992f4db83</cites><orcidid>0000-0002-5167-2099 ; 0000-0002-1040-6229</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdom.13646$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fdom.13646$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,27907,27908,45557,45558</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31002458$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dash, Satya</creatorcontrib><creatorcontrib>Leiter, Lawrence A.</creatorcontrib><title>Residual cardiovascular risk among people with diabetes</title><title>Diabetes, obesity & metabolism</title><addtitle>Diabetes Obes Metab</addtitle><description>Type 2 diabetes (T2D) is a growing health concern across both developed and developing countries. Cardiovascular disease (CVD) remains the major cause of increased mortality in this patient population. In recent years, effective low density lipoprotein lowering treatments and other risk reduction strategies have substantially reduced the risk of atherosclerotic CVD, yet patients with T2D continue to remain at increased risk for atherosclerotic CVD. Here, we will briefly review various proposed underlying mechanisms for this residual risk with a more in‐depth focus on the potential role of triglyceride‐rich lipoproteins in residual risk and potential avenues to target this pharmacologically.</description><subject>Arteriosclerosis</subject><subject>cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>clinical trial</subject><subject>Developing countries</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>dyslipidaemia</subject><subject>LDCs</subject><subject>lipid‐lowering therapy</subject><subject>Lipoproteins</subject><subject>Low density lipoprotein</subject><subject>Metabolic disorders</subject><issn>1462-8902</issn><issn>1463-1326</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp10F1LwzAUBuAgipvTC_-AFLzRi275appcyvyEyUB2X9LkVDvbtSarY__euE4vBHNzwuHh5fAidE7wmIQ3sU09JkxwcYCGhAsWE0bF4e5PY6kwHaAT75cYY85keowGjGBMeSKHKH0BX9pOV5HRzpbNp_amq7SLXOnfI103q9eohaatINqU67fIljqHNfhTdFToysPZfo7Q4v5uMX2MZ_OHp-nNLDYsYSI2hRLEWJlYAEyZTEBKSjCTuZacc61AptqGncVCCsXB5CaVRClacJtLNkJXfWzrmo8O_DqrS2-gqvQKms5nlBKiEqpUEujlH7psOrcKx-0UIzSwoK57ZVzjvYMia11Za7fNCM6-y8xCmdmuzGAv9oldXoP9lT_tBTDpwaasYPt_UnY7f-4jvwA0VHwT</recordid><startdate>201904</startdate><enddate>201904</enddate><creator>Dash, Satya</creator><creator>Leiter, Lawrence A.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5167-2099</orcidid><orcidid>https://orcid.org/0000-0002-1040-6229</orcidid></search><sort><creationdate>201904</creationdate><title>Residual cardiovascular risk among people with diabetes</title><author>Dash, Satya ; Leiter, Lawrence A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3536-cf961cd85dee02385e8821038ba8444a9e87ad882d068694ecbc781992f4db83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Arteriosclerosis</topic><topic>cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>clinical trial</topic><topic>Developing countries</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>dyslipidaemia</topic><topic>LDCs</topic><topic>lipid‐lowering therapy</topic><topic>Lipoproteins</topic><topic>Low density lipoprotein</topic><topic>Metabolic disorders</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dash, Satya</creatorcontrib><creatorcontrib>Leiter, Lawrence A.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes, obesity & metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dash, Satya</au><au>Leiter, Lawrence A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Residual cardiovascular risk among people with diabetes</atitle><jtitle>Diabetes, obesity & metabolism</jtitle><addtitle>Diabetes Obes Metab</addtitle><date>2019-04</date><risdate>2019</risdate><volume>21</volume><issue>S1</issue><spage>28</spage><epage>38</epage><pages>28-38</pages><issn>1462-8902</issn><eissn>1463-1326</eissn><abstract>Type 2 diabetes (T2D) is a growing health concern across both developed and developing countries. Cardiovascular disease (CVD) remains the major cause of increased mortality in this patient population. In recent years, effective low density lipoprotein lowering treatments and other risk reduction strategies have substantially reduced the risk of atherosclerotic CVD, yet patients with T2D continue to remain at increased risk for atherosclerotic CVD. Here, we will briefly review various proposed underlying mechanisms for this residual risk with a more in‐depth focus on the potential role of triglyceride‐rich lipoproteins in residual risk and potential avenues to target this pharmacologically.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>31002458</pmid><doi>10.1111/dom.13646</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-5167-2099</orcidid><orcidid>https://orcid.org/0000-0002-1040-6229</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-8902 |
| ispartof | Diabetes, obesity & metabolism, 2019-04, Vol.21 (S1), p.28-38 |
| issn | 1462-8902 1463-1326 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2211952995 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Arteriosclerosis cardiovascular disease Cardiovascular diseases clinical trial Developing countries Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) dyslipidaemia LDCs lipid‐lowering therapy Lipoproteins Low density lipoprotein Metabolic disorders |
| title | Residual cardiovascular risk among people with diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T08%3A22%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Residual%20cardiovascular%20risk%20among%20people%20with%20diabetes&rft.jtitle=Diabetes,%20obesity%20&%20metabolism&rft.au=Dash,%20Satya&rft.date=2019-04&rft.volume=21&rft.issue=S1&rft.spage=28&rft.epage=38&rft.pages=28-38&rft.issn=1462-8902&rft.eissn=1463-1326&rft_id=info:doi/10.1111/dom.13646&rft_dat=%3Cproquest_cross%3E2211952995%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2211312299&rft_id=info:pmid/31002458&rfr_iscdi=true |